With Antiviral Sales Booming, Gilead Expects A Strong Year
This article was originally published in The Pink Sheet Daily
Executive Summary
While sales for its existing HIV franchise products were very strong, Gilead looks ahead to beginning Phase III of its proprietary "quad" pill.